From 2016 to 2021, the bioreactors market is expected to increase at a CAGR of 6.8%, reaching USD 1,417 million. The study's base year is 2016, and the market size projection is offered for the years 2016 to 2022. The bioreactors market is now being driven by an increase in the adoption of single-use technologies, the usage of hybrid technologies (single-use and stainless steel), and the rising biologics market. This report's goal is to define, describe, and predict the market based on usage, scale, material, control type, end-user, and region. It contains thorough information on the primary influencing elements.
To validate the size of the worldwide bioreactors market and estimate the size of various other dependent submarkets, top-down and bottom-up methodologies were utilised. Secondary research was used to identify the market's major participants, and primary and secondary research was used to determine their market revenues. Primary research comprised extensive interviews with important thought leaders such as CEOs, directors, and marketing executives, as well as secondary research involving the analysis of annual and financial reports of top market competitors.
Secondary sources were used to determine the percentage splits, shares, and breakdowns of the product markets, which were then validated using primary sources. This information is compiled and combined with MarketsandMarkets' thorough inputs and analysis to create this research. The US Food and Drug Administration, Bioprocess International, Biopharma International Supplement, Pharmaceutical Technology Europe, and The World Bank are some of the secondary materials we used.
Sartorius AG (Germany), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), GE Healthcare (A subsidiary of General Electric Company) (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany) are the major OEM/system integrator players in this report, while major EPC players are Amec Foster Wheeler plc (U.K.), Fluor Corporation (U.S.), Jacobs Engineering (France).
MarketsandMarkets provides adaptations based on the provided market data to meet the company's particular needs. The following report customization options are available:
We personalise the MNM assessments to match your company's specific demands, in addition to market data. Customize to acquire a full analysis of the following parameters: product analysis, brand/product perception matrix, porters five force analysis, regulatory framework, and competitive intelligence.
Between 2016 and 2021, the global bioreactors market is estimated to grow at a CAGR of 6.8%, reaching USD 1,417 million. The bioreactors market is rising due to a rise in the adoption of single-use technologies, the usage of hybrid technologies (single-use and stainless steel), the growing popularity of single-use bioreactors among biopharmaceutical businesses, and the growing biologics market. However, regulatory worries about single-use bioreactors, as well as challenges with leachable and extractable materials in single-use bags, are impeding the market's growth.
End-users, usage, scale, material, control kinds, and suppliers are all divided in the worldwide bioreactor market. The geographical analysis also includes North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
During the projected period from 2016 to 2021, single-use bioreactors are expected to expand at the second fastest rate by volume. The advantages of SUBs, such as reduced cleaning and sterilisation requirements, lower danger of cross contamination, and greater control over aseptic conditions, are credited with the segment's rapid rise. SUBs improve the end product's quality by lowering automation complexity. In the case of stainless steel bioreactors, the number of in and out points increases the bioreactor's complexity. There are numerous locations in stainless steel bioreactors that must be monitored for valve control or temperature monitoring.
SUBs, on the other hand, have fewer pipes, valves, and instruments as a result of the superior design, requiring less valve control and temperature monitoring. Because SUBs have less design complications, they don't require surface cleaning, which avoids contamination and cross-contamination of cultures, which is a key issue with standard bioreactors. As a result, SUBs have a simpler overall production process than regular bioreactors.
Comments
Post a Comment